Not exact matches
«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this
research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian
cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of
Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.
An oral
cancer drug improves outcomes while minimizing side effects in women with
gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary
research.
Another student who was using phage - display technology to identify new molecular markers in ovarian
cancer attended a clinic in
gynecologic oncology once a week throughout her dissertation
research.
Research from Rutgers
Cancer Institute of New Jersey examining
gynecologic cancers that poorly respond to therapy shows genomic profiling can help identify alternate and targeted treatments.
Women with Stage III ovarian
cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Med
cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the
Gynecologic Oncology Group (GOG), a National
Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Med
Cancer Institute - supported
research network, in the January 5, 2006 issue of the New England Journal of Medicine.
Dr. Kunle Odunsi is the deputy director of the Roswell Park
Cancer Institute, where he also serves as the chair of the Department of
Gynecologic Oncology, the executive director of the Center for Immunotherapy, and the co-Leader of the Tumor Immunology and Immunotherapy
research program.
Her professional and
research interests include familial
gynecologic cancers;
cancer susceptibility in rare genetic syndromes; and psychosocial counseling in
cancer - prone families.
Topics and models to be covered include: nomenclature, basic mouse genetics, concepts of mouse model generation, approaches to working up mutant mice, role of pathologists at
research institutions, systemic, hematopoietic, mammary,
gynecologic, cutaneous, infectious and immune system pathology, embryology and
cancer models.
My primary
research focus has been in the use of individualized approach in the management of
gynecologic cancer, extremity soft tissue sarcoma through molecular markers and precision radiotherapy.
2011 -
Research Affiliate (Postdoctoral)- Department of
Gynecologic Oncology, Roswell Park Comprehensive
Cancer Center, Buffalo, NY
RESEARCH INTERESTS: The Drapkin laboratory focuses on developing a comprehensive understanding of the genetic, molecular and physiological factors that drive the development of
cancer, with a special focus on
gynecologic malignancies.
In an interdisciplinary collaboration, the University of Pennsylvania School of Veterinary Medicine's Working Dog Center (photo above courtesy of University of Pennsylvania), the School of Arts and Science's Department of Physics and Astronomy, Penn Medicine's Division of
Gynecologic Oncology, and the Monell Chemical Senses Center have joined together for a
research investigation using canine olfaction, along with chemical and nanotechnology analysis, to detect early - stage human ovarian
cancer.
Their mission is to promote the highest quality of comprehensive clinical care through education and
research in the prevention and treatment of
gynecologic cancers.